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Accepted 7 October 2013Oral busulfan is an alkylating agent that provides good
antileukemic activity and excellent CNS penetration. It
was ﬁrst introduced over 30 years ago by George Santos
as an alternative to total body irradiation (TBI) for pre-
allogeneic transplantation conditioning [1]. Since its intro-
duction, it has had a mixed reputation. Oral busulfan (PO
BU) proved an attractive alternative to TBI based on general
availability, ease of administration, and low cost. Although
the results of early randomized controlled trials were
mixed, in some settings, such as sibling donor allogeneic
bone marrow transplantations for chronic myeloid leuke-
mia, PO BU- and TBI-based conditioning regimen trans-
plantations resulted in similar outcomes [2]. Since the
mid-1990s, PO BU has been 1 of the main conditioning
agents for allogeneic transplantation.
Despite this, PO BU has always carried with it the
shadow of signiﬁcant intra- and inter-patient variability
in absorption and ﬁrst pass metabolism that contributes to
a risk of veno-occlusive disease/sinusoidal obstruction
syndrome (VOD/SOS) that can result in signiﬁcant morbidity
and death in some patients. To address these metabolic
limitations, an intravenous formulation of the drug was
developed and approved for use in allogeneic trans-
plantation in 1999. Compared to PO BU, the intravenous
formulation of busulfan (IV BU) resulted in less patient-to-
patient variability in metabolism, drug exposure, and early
toxicities [3]. Early reports suggested that compared with
PO BU, IV BU resulted in lower early toxicities, such as VOD/
SOS, and decreased treatment-related mortality [4-6]. IV BU
use has steadily increased at the expense of both PO BU and
TBI. Novel dosing regimens, particularly once a day, became
another attractive feature of IV BU. Although more expen-
sive to purchase, the perceived advantages and convenience
with IV BU has led many programs to switch from PO to
IV BU.
With experience, however, we learned that it was not as
simple as we had hoped. There remains patient-to-patientFinancial disclosure: See Acknowledgments on page 1658.
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The hope for a simple weight-based dose, as originally
introduced, has not been borne out by practice. Therapeutic
drug monitoring (TDM) based on the pharmacokinetics of
the ﬁrst therapeutic dose or test dose has led to a better
understanding of therapeutic range for busulfan (AUC 900
to 1500 micromole  min), above which the risk of toxicity,
particularly VOD/SOS, increases [7,8]. At the other end, low
doses have been associated with relapse or graft failure,
albeit primarily in children [9]. In a recent Center for In-
ternational Blood and Marrow Transplant Research study of
IV BU, 58% of adult patients receiving ablative IV BU-based
conditioning had TDM performed [10]. TDM is close to
universal in the pediatric setting because of the more
marked variability based on size and changing metabolism
with age.
Recently, there has even been a ﬂurry of publications
that have revisited the BU versus TBI debate based largely
on the phase 2 data and experience with IV BU and antici-
pation that, perhaps now, BU would result in similar or
perhaps better outcomes than TBI. This has largely been
conﬁrmed in prospective and retrospective cohort studies
from the Center for International Blood and Marrow
Transplant Research and European Group for Blood and
Marrow Transplantation [10,11]. Still the migration to IV BU
has not been complete and very good transplantation re-
sults when PO BU is combined with TDM (ie, targeted
busulfan) have been reported [12]. Results appear equiva-
lent to those achieved with IV BU.
This is the question addressed by Kato et al. in this issue of
Biology of Blood and Marrow Transplantation: Are results with
PO BU similar to those with IV BU [13]? Their interest in
pediatric patients as previously reported data in that setting
is quite limited. To address the question, they analyzed data
on 460 children receiving a myeloablative conditioning
allogeneic transplantation using either PO BU or IV BU and
reported to the Japanese Society for Hematopoietic Cell
Transplantation Registry between 2000 and 2010. Sixty
percent of the children were between 1 and 10 years of age
and underwent transplantation for either acutemyelogenous
leukemia or acute lymphoblastic leukemia, primarily in
complete remission. Approximately 40% of donors were
related, 43% cord, and the remainder were volunteer unre-
lated or unknown. A quarter had received a prior trans-
plantation. Of note, very few patients received IV BU prior to
2004 and very few received PO BU after 2007. Essentially,
this is a study of before and after introduction of IV BU in
Japan. There were no signiﬁcant differences in 3-year sur-
vival, nonrelapsemortality, relapse or the incidence of grades
II to IV acute graft-versus-host disease for patients receiving
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acute myelogenous leukemia or acute lymphoblastic leuke-
mia separately. VOD/SOS incidences with IV BU and PO BU
were 30.3% and 27.4%, respectively (P ¼ .74). In multivariate
analysis, route of BU dosing (IV versus PO) was not associated
with the outcomes of interest. Essentially, no meaningful
differences in the results with IV BU versus PO BU were
found: IV BU did not improve outcomes in this pediatric
population.
There are, unfortunately, several key pieces of data that
are not reported but are essential if one is to consider
changing practice based on this report. The most critical gap
is whether any, some, or all patients had TDM and BU dose
adjustments. In many reports, TDM with BU is reported as
essential in pediatrics. Without knowing what was done
with regards to TDM and dose adjustments, the results of
this study cannot be extrapolated to other centers. Also of
importance are data regarding dose and schedule of the BU
administration. We would also like to know how many
centers contributed patients and whether all patients who
underwent transplantation are reported to the Japanese
Society for Hematopoietic Cell Transplantation Registry or
whether it is voluntary. Registry-based research is a tricky
business and to prevent unwarranted criticism, it is vital
that critical details regarding the structure and processes of
the registry be included in the methods. Somewhat
different than what has occurred in many registry studies
evaluating different therapeutic strategies, patient selection
for IV versus PO BU in this report is primarily a function of
time; more recent patients received IV BU and earlier pa-
tients PO. Bias in treatment assignment is likely less in this
report than in many other registry studies. Similarly,
because the IV BU patients underwent transplantationmore
recently, any advantage afforded by improvements in sup-
portive care would favor the IV group, strengthening the
argument that IV BU has itself not resulted in improvement
in outcomes.
How, then, to interpret this study? If we acknowledge the
limitations of the study report and accept the results that IV
and PO BU resulted in similar outcomes in this pediatric
population, does this meanwe should abandon IV BU and go
back to PO? No, I don’t think that is the take-home message.
Instead, each center has to consider all the local variables and
practice drivers that would favor using 1 form of BU over the
other. For our adult program, the local advantages of IV BU
including once a day administration, decreased nursing and
pharmacy time, patient preference, and less need for TDM
(although that is still a topic of much debate) mean that we
are staying with IV BU. For other centers that have not
switched to IV BU, I think these data are reassuring that they
are not doing something wrong or short changing their
patients.
The most important thing about the mechanics of trans-
plantation is to do a limited number of things, understand
what you do, and do them well. This applies equally to BU
and conditioning regimens, whether IV or PO. Determine
best practices for your local circumstances, continuously
evaluate your outcomes, and be willing to consider newapproaches that report improved outcomes supported by
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